Lung cancer screening: achieving more by intervening less

Affiliations

¹ Rush University, Chicago, IL 60612, USA. Electronic address: jmulshin@rush.edu.
² Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Comment

James L Mulshine et al. Lancet Oncol. 2014 Nov.

. 2014 Nov;15(12):1284-5.

doi: 10.1016/S1470-2045(14)70418-8. Epub 2014 Oct 1.

¹ Rush University, Chicago, IL 60612, USA. Electronic address: jmulshin@rush.edu.
² Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

No abstract available

Comment in

Lung cancer screening with low-dose CT: more questions than answers.
Ruano-Ravina A, Pérez-Ríos M. Ruano-Ravina A, et al. Lancet Oncol. 2015 Jan;16(1):e3-4. doi: 10.1016/S1470-2045(14)71157-X. Epub 2014 Dec 29. Lancet Oncol. 2015. PMID: 25638551 No abstract available.
Lung cancer screening with low-dose CT: more questions than answers--author's reply.
Mulshine JL. Mulshine JL. Lancet Oncol. 2015 Jan;16(1):e4. doi: 10.1016/S1470-2045(14)71163-5. Epub 2014 Dec 29. Lancet Oncol. 2015. PMID: 25638555 No abstract available.

Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, Nackaerts K, Vliegenthart R, ten Haaf K, Yousaf-Khan UA, Heuvelmans MA, Thunnissen E, Oudkerk M, Mali W, de Koning HJ. Horeweg N, et al. Lancet Oncol. 2014 Nov;15(12):1342-50. doi: 10.1016/S1470-2045(14)70387-0. Epub 2014 Oct 1. Lancet Oncol. 2014. PMID: 25282284 Clinical Trial.
Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, ten Haaf K, Nackaerts K, Lammers JW, Weenink C, Groen HJ, van Ooijen P, de Jong PA, de Bock GH, Mali W, de Koning HJ, Oudkerk M. Horeweg N, et al. Lancet Oncol. 2014 Nov;15(12):1332-41. doi: 10.1016/S1470-2045(14)70389-4. Epub 2014 Oct 1. Lancet Oncol. 2014. PMID: 25282285 Clinical Trial.